SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher ® prostate cancer test to FEDMED Payors. FEDMED is ...
Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
SOUTH SAN FRANCISCO, Calif., February 11, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be ...
Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...
Imagine having increased muscle weakness for two years before figuring out the cause. That is the shared experience of myasthenia gravis patients. Canadian startup Decipher MedTech is developing a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback